

**UNITED STATES DISTRICT COURT  
DISTRICT OF MASSACHUSETTS**

UNITED STATES OF AMERICA,

Plaintiff,

V.

No. 20-cv-11548-NMG

TEVA PHARMACEUTICALS USA, INC., and

TEVA NEUROSCIENCE, INC.,

Defendants.

**JOINT MOTION FOR ENTRY OF STIPULATED PROTECTIVE ORDER**

Pursuant to Rule 26(c) of the Federal Rules of Civil Procedure, Plaintiff, the United States of America, and Defendants, Teva Pharmaceuticals USA, Inc. and Teva Neuroscience, Inc., by their undersigned counsel, respectfully submit the following Joint Motion for Stipulated Protective Order, and state as follows:

1. The parties have agreed to entry of a protective order in this case, and, as explained in greater detail below, affirmatively state that there is good cause supporting the entry of such an order.
2. On August 18, 2020, the United States filed the Complaint in this case, asserting claims for alleged violations of the False Claims Act.
3. The parties anticipate that discovery in this matter may involve the disclosure of confidential information, including: pricing data governed by the confidentiality provisions of the Social Security Act; confidential health information; trade secret or other confidential research or development information; commercial information that bears upon a party's or third-

party's competitive position; personnel files; sensitive personal information; and financial account numbers.

4. Rule 26(c) of the Federal Rules of Civil Procedure authorizes the Court, upon a showing of good cause and as justice may require, to enter a protective order to limit dissemination of confidential information. *See* Fed. R. Civ. P. 26(c); *Poliquin v. Garden Way, Inc.*, 989 F.2d 527, 532 (1st Cir. 1993) (stating the Court has “broad discretion to decide when a protective order is appropriate and what degree of protection is required.”).

5. The parties agree that entry of the [Proposed] Confidentiality Agreement and Stipulated Protective Order, attached hereto, will protect the confidential information of the parties and third-parties in this case and protect the parties from undue burden and oppression.

WHEREFORE, the parties respectfully request that the Court enter the [Proposed] Confidentiality Agreement and Stipulated Protective Order attached as Exhibit A hereto.

Dated: December 16, 2021

Respectfully submitted,

BRIAN M. BOYNTON  
Acting Assistant Attorney General

TEVA PHARMACEUTICALS USA, INC.  
TEVA NEUROSCIENCE, INC.

NATHANIEL R. MENDELL  
Acting United States Attorney

By its attorneys,

/s/ Diane C. Seol  
ABRAHAM R. GEORGE  
EVAN D. PANICH  
DIANE C. SEOL  
Assistant United States Attorneys

/s/ Emily Renshaw  
Emily Renshaw (BBO #675316)  
Morgan, Lewis & Bockius LLP  
One Federal Street  
Boston, MA 02110-1726  
Tel: 617.951.8000  
emily.renshaw@morganlewis.com

One Courthouse Way, Suite 9200  
Boston, MA 02210  
Phone: (617) 748-3100  
abraham.george@usdoj.gov  
evan.panich@usdoj.gov  
diane.seol@usdoj.gov

Eric Sitarchuk (*pro hac vice*)  
Alison Tanchyk (*pro hac vice*)  
William T. McEnroe (*pro hac vice*)  
Richard Shephard (*pro hac vice*)  
Morgan, Lewis & Bockius LLP  
1701 Market Street  
Philadelphia, PA 19103-2921  
Tel: 215.963.5000  
eric.sitarchuk@morganlewis.com  
alison.tanchyk@morganlewis.com  
william.mcenroe@morganlewis.com  
richard.shephard@morganlewis.com

JAMIE A. YAVELBERG  
ANDY J. MAO  
DOUGLAS J. ROSENTHAL  
NELSON D. WAGNER  
Attorneys, Commercial Litigation Branch  
U.S. Department of Justice  
175 N St. NE, Room 9.111  
Washington, DC 20002  
Phone: (202) 305-2073  
douglas.j.rosenthal@usdoj.gov  
nelson.wagner2@usdoj.gov